RecruitingNCT06042387
Genome Analysis Across Populations in Inflammatory Bowel Disease
Sponsor
Mount Sinai Hospital, Canada
Enrollment
150 participants
Start Date
May 1, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Objective: To use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to IBD within affected populations.
Eligibility
Inclusion Criteria4
- Subjects: diagnosed with Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis, IBD-undetermined)
- Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U))
- Healthy controls: no personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss
- Any age
Exclusion Criteria1
- \- Subjects with other gastrointestinal conditions not meeting the above IBD or Healthy Control criteria
Interventions
GENETICBlood or saliva sample collection
Blood or saliva sample \& clinical data collection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06042387
Related Trials
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
Combined Immunosuppression for Pediatric Crohn's Disease
NCT050438701 location
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
NCT0658132891 locations
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
NCT060713121 location